Centralised marketing authorisation procedure in the EU
The Centralised Procedure (CP) allows pharmaceutical companies to obtain a single marketing authorisation valid across all EU Member States and the EEA.
This procedure is mandatory for certain categories of innovative medicines, such as biotechnologies and advanced therapies.
Managed by the EMA, the process results in a final decision by the European Commission, granting or refusing the authorisation.
